Clinical Trials Logo

Acquired Thrombotic Thrombocytopenic Purpura clinical trials

View clinical trials related to Acquired Thrombotic Thrombocytopenic Purpura.

Filter by:
  • None
  • Page 1

NCT ID: NCT04021173 Not yet recruiting - Clinical trials for Acquired Thrombotic Thrombocytopenic Purpura

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Start date: July 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical study. It is planned to recruit 74 patients with acquired thrombotic thrombocytopenic purpura (TTP). To evaluate the efficacy and safety of Anfibatide as an adjuvant therapy for plasma exchange in patients with acquired TTP.

NCT ID: NCT02878603 Completed - Clinical trials for Acquired Thrombotic Thrombocytopenic Purpura

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Start date: October 2016
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long term impact of TTP.

NCT ID: NCT02553317 Completed - Clinical trials for Acquired Thrombotic Thrombocytopenic Purpura

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

HERCULES
Start date: November 2015
Phase: Phase 3
Study type: Interventional

The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

NCT ID: NCT01151423 Completed - Clinical trials for Acquired Thrombotic Thrombocytopenic Purpura

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

TITAN
Start date: January 2011
Phase: Phase 2
Study type: Interventional

This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP. Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange (PE).